Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX340 · 1 trial · 1 indication
To evaluate the safety and tolerability of a single ascending dose of CTX340 in participants with hypertension to determine the recommended Phase 2 dose (RP2D).
To evaluate the pharmacodynamics (PD) effect of CTX340 at the recommended Phase 2 dose (RP2D)
| Arm | Type | Description |
|---|---|---|
| Phase 1: CTX340 | EXPERIMENTAL | Phase 1 is An Open-Label, Ascending Dose Design. |
| Phase 2: Recommended Phase 2 Dose CTX340 | EXPERIMENTAL | Phase 2: Recommended Phase 2 Dose CTX340. |
| Phase 2: Placebo | EXPERIMENTAL | Phase 2: Placebo. |
| Name | Type | Description |
|---|---|---|
| CTX340 | DRUG | CTX340 is an in vivo gene editing therapy designed to utilize clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9) to target and disrupt human angiotensinogen (AGT) gene in liver. |
| Placebo | DRUG | One of the arms in Phase 2 will be placebo. |
Key Inclusion Criteria: 1. Age: ≥18 and ≤75 years. 2. Body mass index ≤40 kg/m2. 3. 24-hour mean ambulatory blood pressure monitoring (ABPM) systolic blood pressure (SBP) measurement of ≥130 mm Hg but ≤160 mm Hg despite treatment 4. Be on treatment with ≥4 antihypertensive therapies at effective do...
CTX340 is an investigational small molecule being developed for the treatment of hypertension, a cardiovascular condition characterized by chronically elevated blood pressure. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
CTX340 targets the AGT gene, which encodes angiotensinogen, a key precursor in the renin-angiotensin system that regulates blood pressure. By targeting this gene, CTX340 aims to modulate the production of angiotensinogen to potentially lower blood pressure in patients with hypertension.
CTX340 is being developed by CRISPR Therapeutics AG, a biopharmaceutical company publicly traded under the ticker symbol CRSP. The company is conducting clinical trials to evaluate the safety, tolerability, and efficacy of CTX340 in participants with hypertension.
CTX340 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies and is still undergoing clinical trials to assess its safety and efficacy in humans.
CTX340 is being evaluated in a Phase 1 clinical trial with the identifier NCT07758634. This trial is recruiting participants with hypertension in the United States and Australia, with a planned enrollment of 69 participants aged 18 years and older.